Probiotec Ltd
ASX:PBP

Watchlist Manager
Probiotec Ltd Logo
Probiotec Ltd
ASX:PBP
Watchlist
Price: 2.98 AUD
Market Cap: 242.3m AUD

Relative Value

There is not enough data to reliably calculate the relative value of PBP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PBP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
1.1
Median 5Y
1.1
Industry
2.6
Forward
1
vs History
vs Industry
Median 3Y
27.9
Median 5Y
27.9
Industry
21.7
Forward
16.4
vs History
vs Industry
Median 3Y
15.5
Median 5Y
14.1
Industry
16.6
vs History
vs Industry
Median 3Y
81.5
Median 5Y
25.4
Industry
22.5
vs History
vs Industry
Median 3Y
2.7
Median 5Y
2.4
Industry
2.3
vs History
vs Industry
Median 3Y
1.4
Median 5Y
1.4
Industry
2.9
Forward
1.3
vs History
vs Industry
Median 3Y
4.7
Median 5Y
4.7
Industry
5.5
vs History
vs Industry
Median 3Y
15.4
Median 5Y
15.4
Industry
13.1
Forward
7.8
vs History
vs Industry
Median 3Y
15.4
Median 5Y
15.4
Industry
16.6
Forward
12.3
vs History
vs Industry
Median 3Y
19.7
Median 5Y
17.3
Industry
15.8
vs History
vs Industry
Median 3Y
64.2
Median 5Y
32.8
Industry
19.1
vs History
vs Industry
Median 3Y
1.6
Median 5Y
1.4
Industry
1.9

Multiples Across Competitors

PBP Competitors Multiples
Probiotec Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Probiotec Ltd
ASX:PBP
242.3m AUD 1.1 27.9 15.4 15.4
US
Eli Lilly and Co
NYSE:LLY
954.7B USD 16.1 51.9 34.8 37.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
505.3B USD 5.5 20.1 16.4 21.3
CH
Roche Holding AG
SIX:ROG
252.4B CHF 4.1 26.8 11.5 13.4
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP 4.9 30.1 108.4 158.7
CH
Novartis AG
SIX:NOVN
203.1B CHF 4.6 17.8 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
245.9B USD 3.8 12.9 9.2 10.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.5 13.6 9.5 11.1
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
147.4B USD 2.3 15 7.6 10.4
P/E Multiple
Earnings Growth PEG
AU
Probiotec Ltd
ASX:PBP
Average P/E: 24
27.9
20%
1.4
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.1
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.8
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
17.8
17%
1
US
Merck & Co Inc
NYSE:MRK
12.9
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
4%
3.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Probiotec Ltd
ASX:PBP
Average EV/EBITDA: 399.2
15.4
35%
0.4
US
Eli Lilly and Co
NYSE:LLY
34.8
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.4
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.4
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.2
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.5
2%
4.8
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Probiotec Ltd
ASX:PBP
Average EV/EBIT: 1 709.2
15.4
16%
1
US
Eli Lilly and Co
NYSE:LLY
37.3
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21.3
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.4
5%
2.7
UK
AstraZeneca PLC
LSE:AZN
158.7
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
10.9
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.1
1%
11.1
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3